Key result
Inhibition of mir128-3p or restoration of MAPK7/CEBPβ signaling preserved IRS1 expression, mitigated myocardial insulin resistance, and ameliorated cardiac dysfunction post-myocardial infarction in mice.
Why the study?
Myocardial insulin resistance contributes to heart failure under pathological stresses, necessitating investigation into therapeutic strategies to preserve cardiac insulin pathways.
Does targeting mir128-3p or restoring MAPK7/CEBPβ improve cardiac dysfunction and insulin resistance in post-MI heart failure models?
Does targeting mir128-3p or restoring MAPK7/CEBPβ improve cardiac dysfunction and insulin resistance in post-MI heart failure models?
Targeting mir128-3p or its upstream regulators mitigates myocardial insulin resistance and slows heart failure progression post-ischemia in preclinical models.
Mir128-3p inhibition may mitigate post-MI insulin resistance and dysfunction in mice; leaves open translation to human heart failure therapy.
Myocardial insulin resistance contributes to heart failure in response to pathological stresses, therefore, a therapeutic strategy to maintain cardiac insulin pathways requires further investigation. We demonstrated that insulin receptor substrate 1 (IRS1) was reduced in failing mouse hearts post-myocardial infarction (MI) and failing human hearts. The mice manifesting severe cardiac dysfunction post-MI displayed elevated mir128-3p in the myocardium. Ischemia-upregulated mir128-3p promoted Irs1 degradation. Using rat cardiomyocytes and human-induced pluripotent stem cell-derived cardiomyocytes, we elucidated that mitogen-activated protein kinase 7 (MAPK7, also known as ERK5)-mediated CCAAT/enhancer-binding protein beta (CEBPβ) transcriptionally represses mir128-3p under hypoxia. Therapeutically, functional studies demonstrated gene therapy-delivered cardiac-specific MAPK7 restoration or overexpression of CEBPβ impeded cardiac injury after MI, at least partly due to normalization of mir128-3p. Furthermore, inhibition of mir128-3p preserved Irs1 and ameliorated cardiac dysfunction post-MI. In conclusion, we reveal that targeting mir128-3p mitigates myocardial insulin resistance, thereafter slowing down the progression of heart failure post-ischemia.
No takes yet. Share an insight, caveat, or question.
Ruiz‐Velasco et al. (2020) studied Ischemia-induced heart failure. mir128-3p inhibition or MAPK7/CEBPβ restoration vs. Sham or control vector was evaluated on Cardiac function and IRS1 expression. Inhibition of mir128-3p or restoration of MAPK7/CEBPβ signaling preserved IRS1 expression, mitigated myocardial insulin resistance, and ameliorated cardiac dysfunction post-myocardial infarction in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: